More Alzheimer's Pain As J&J Pulls Plug On BACE Inhibitor
J&J's Janssen unit is ending development of atabecestat after serious elevations of liver enzymes were seen in some patients who received the drug, increasing doubts about the BACE inhibitor mechanism as an appropriate target.
You may also be interested in...
An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.